Protalix BioTherapeutics, Inc. - COM (PLX)

Q3 2020 13F Holders as of 9/30/2020

Type / Class
Equity / COM
Number of holders
22
Total 13F shares, excl. options
4.76M
Shares change
-499K
Total reported value, excl. options
$18.4M
Value change
-$1.92M
Put/Call ratio
0.24
Number of buys
10
Number of sells
-8
Price
$3.87

Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q3 2020

32 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q3 2020.
Protalix BioTherapeutics, Inc. - COM (PLX) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4.76M shares .
Largest 10 shareholders include HIGHBRIDGE CAPITAL MANAGEMENT LLC (2.41M shares), RENAISSANCE TECHNOLOGIES LLC (490K shares), Psagot Investment House Ltd. (470K shares), UBS OCONNOR LLC (300K shares), BRIDGEWAY CAPITAL MANAGEMENT INC (213K shares), Phoenix Holdings Ltd. (204K shares), BANK OF MONTREAL /CAN/ (161K shares), KENNEDY CAPITAL MANAGEMENT, INC. (149K shares), ETF MANAGERS GROUP, LLC (102K shares), and CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM (66.6K shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.